Plus   Neg

Fresenius Medical Care Q4 Profit Down 48% - Quick Facts

Fresenius Medical Care AG & Co. KGaA (FMS) reported that its fourth-quarter net income attributable to shareholders declined 48% to 177 million euros from last year, while it was down 43% at constant currency, hurt by impairment in the Latin America region and accelerated excess mortality due to COVID-19. Basic earnings per share decreased by 47% or 42% at constant currency to 0.61 euros from the previous year.

Excluding the Latin America impairment and on an adjusted 2019 basis, net income for the quarter grew by 1% to 372 million euros from the prior year.

Operating income declined by 25% or 18% at constant currency to 462 million euros from the prior year, due to a macro-economically driven impairment of goodwill and trade names in the Latin America segment, unfavorable COVID-19 effects and a lower reimbursement for calcimimetics.

Quarterly revenue decreased 4% to 4.40 billion euros from last year, while it was up 4% at constant currency. Organic growth of 1% was realized including the expected negative impacts from lower reimbursement for calcimimetics and COVID-19-related slower treatment growth.

The company plans to propose a dividend of 1.34 euros per share to the annual general meeting in May 2021. The proposal would result in the 24th consecutive dividend increase.

Looking ahead for 2021, the company expects revenue to grow at a low- to mid-single digit percentage rate and net income to decline at a high-teens to mid-twenties percentage rate against the higher than expected 2020 base.

The company confirmed its 2025 targets that are based on the company's mid-term strategy. It assumes that FME25 compensates for the anticipated COVID-19-related effects. Until 2025 the company expects compounded annual average increases in the mid-single-digit percentage range for revenue and in the high-single-digit percentage range for net income.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Intel Corp's Mobileye and self-driving delivery startup Udelv have signed a deal to launch a fully driverless delivery service in the United States by 2023. The companies plan to produce more than 35,000 Mobileye-driven Transporters by 2028. Domino's Pizza and autonomous vehicle startup Nuro are launching autonomous pizza delivery in Houston, this week. Some Domino's customers in Houston can have a pizza delivered by Nuro's R2 robot. CVS Health is now offering cost COVID-19 vaccines at select CVS Pharmacy locations in four more U.S. states as part of its ongoing effort to expand access to COVID-19 vaccines. It has now expanded the program to 51 more select locations in Arkansas, Nebraska, Iowa and Maine. It began in Washington, West Virginia, Delaware and New Mexico at 15 select locations from March 31.
Follow RTT